

Infected cell vaccines in the treatment of acute leukemia: laying the groundwork for a clinical trial

Oct. 14, 2016 to October 1, 2018

Highlights

- Personalized strategy with a virus-infected leukemia cell vaccine can offer more ammunition against acute leukemia
- Vaccine strategy combines cancer-killing viruses with the added ability to stimulate the patient's own immune system against their leukemia
- Creates the foundation for further studies that will bring this new approach for the treatment of leukemia towards a clinical trial
- Leukemia vaccines are being created in a number of ways, but the use of oncolytic viruses as part of the vaccine is a novel approach

About the project

Acute leukemia is a type of blood cancer that remains difficult to treat with standard therapies, most of which are dangerous and associated with a high risk of complications and death. Despite aggressive chemotherapy and stem cell transplantation, less than 5% of patients with relapsed acute leukemia are cured. Patients with acute leukemia need more ammunition against their disease. This project proposes that a personalized strategy with a virus-infected leukemia cell vaccine can offer just that needed ammunition.

This vaccine strategy combines cancer-killing viruses, an existing BioCanRx technology, with the added ability to stimulate the patient's own immune system against his/her leukemia. This strategy would provide patients with a less toxic and more personalized approach to defeating leukemia. Based upon on their discovery that infected leukemia cell vaccines induce a protective leukemia specific immune response in mice, they propose to test in a clinical trial, whether vaccines created using a patient's own leukemia cells infected with a cancer-killing virus and inactivated with radiation can protect

Acute leukemia

The goal at the end of this project is to have the necessary pre-clinical package to support a pre-CTA meeting with Health Canada to address toxicology studies needed for the clinical trial testing the safety and feasibility of using oncolytic virus-infected and gamma-irradiated leukemia cell vaccines in patients with acute leukemia.

targeted cancers

Project value

\$275,860
BioCanRX contribution:
\$155,888

Partners

6

Biotherapeutics

Maraba MG1

BioCanRx core facilities

2

Molecular Cellular Immunology Core (Vancouver)

Human Immune Testing Suite (Hamilton)



TURNSTONE
BIOLOGICS



Cancer Research Society



against leukemic relapse. This infected cell vaccine will be tested in mice under conditions that mimic those of patients enrolled in such a trial. The initial experiments will be performed using the Maraba MG1 virus and murine leukemia cell lines. The proposed experiments will test the effect of chemotherapy on the infected cell vaccine response while further experiments will determine the ideal manufacturing and storage conditions needed for an effective vaccine. Completion of this project will create the foundation for further studies that will ultimately bring this new approach for the treatment of leukemia towards a clinical trial. This vaccine strategy will offer a uniquely tailored therapy to each patient with leukemia, providing patients with these aggressive cancers a chance at cure.

Key investigators

Project lead:

Dr. Natasha Kekre

Principal Investigators

Dr. Harold Atkins
Dr. John Bell




The Ottawa Hospital
RESEARCH INSTITUTE

L'Hôpital d'Ottawa
INSTITUT DE RECHERCHE



uOttawa

Catalyst Program Investigators



Hamilton
 McMaster University
 Dr. Brian Lichty

Ottawa
 Ottawa Hospital Research Institute,
 The Ottawa Hospital,
 University of Ottawa
 Dr. Natasha Kekre
 Dr. Harold Atkins
 Dr. John Bell
 Dr. Mitchell Sabloff
 Dr. Rebecca Auer

Partners		
Bone Marrow Transplantation Foundation, The Ottawa Hospital \$40,000	The Ottawa Hospital Foundation \$20,000	Turnstone Biologics \$10,000 (in-kind)
Hematology Division, The Ottawa Hospital \$20,000 (in-kind)	Ottawa Regional Cancer Foundation \$53,916	Cancer Research Society \$29,972

About, continued...

This project will develop an infected cell vaccine, a personalized immunotherapy, as a possible approach to treating patients with refractory leukemia or those unable to safely receive chemotherapy. Leukemia vaccines are being created in a number of ways, but the use of oncolytic viruses as part of the vaccine remains a novel approach. This proposal brings new clinical and biologic expertise in hematologic malignancies into the BioCanRx organization, including stem cell transplantation, a field in which clinicians are already comfortable with adopting new immune therapies in the clinic.

Key Milestones

October 2016 – January 2017

- Murine experimental design
- Ethics application for patient samples

March 2018 – October 2018

- Manufacture and characterize ILCV with patient samples

October 2016 – October 2017

- Murine survival experiments
- Immune assays for immune response and potency to ILCV

January 2017 – January 2018

- Banking patient samples

October 2017 – March 2018

- Compare methods of ILCV cryopreservation and production with patient samples

June 2018 – October 2018

- Validate potency assay in patient samples

The power to kill cancer lies within us.
 Let's tell our bodies how.

